Form 8-K - Current report:
SEC Accession No. 0001558370-25-011579
Filing Date
2025-08-14
Accepted
2025-08-14 16:31:12
Documents
12
Period of Report
2025-08-14
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K adap-20250814x8k.htm   iXBRL 8-K 36684
  Complete submission text file 0001558370-25-011579.txt   151299

Data Files

Seq Description Document Type Size
2 EX-101.SCH adap-20250814.xsd EX-101.SCH 3898
3 EX-101.LAB adap-20250814_lab.xml EX-101.LAB 15972
4 EX-101.PRE adap-20250814_pre.xml EX-101.PRE 10791
14 EXTRACTED XBRL INSTANCE DOCUMENT adap-20250814x8k_htm.xml XML 4914
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE United Kingdom
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE United Kingdom 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37368 | Film No.: 251219937
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)